Menu Search
Equities

RemeGen Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
REG:DUS

RemeGen Co Ltd

Actions
  • Price (EUR)8.65
  • Today's Change0.35 / 4.22%
  • Shares traded1.00k
  • 1 Year change+372.68%
  • Beta1.1039
Data delayed at least 15 minutes, as of Feb 10 2026 08:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

RemeGen Co Ltd is a China-based company principally engaged in biopharmaceutical research, biopharmaceutical service, biopharmaceutical production and sale. The Company focuses on therapeutic antibody drugs such as antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company’s main products include telitacicept, disitamab vedotin, RC28-E and others. The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly operates its businesses in the domestic and overseas markets.

  • Revenue in HKD (TTM)2.32bn
  • Net income in HKD-1.28bn
  • Incorporated2008
  • Employees3.07k
  • Location
    RemeGen Co LtdNo.1 Rongchang Road, Yantai ETDZYANTAI 264006ChinaCHN
  • Phone+86 5 353573685
  • Fax+86 5 356113517
  • Websitehttps://www.remegen.cn/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.